Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $12.7 million.

  • Niagen Bioscience's Accounts Payables rose 8458.64% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 8458.64%. This contributed to the annual value of $8.5 million for FY2024, which is 1667.32% down from last year.
  • Niagen Bioscience's Accounts Payables amounted to $12.7 million in Q3 2025, which was up 8458.64% from $13.7 million recorded in Q2 2025.
  • Niagen Bioscience's Accounts Payables' 5-year high stood at $13.7 million during Q2 2025, with a 5-year trough of $6.9 million in Q3 2024.
  • For the 5-year period, Niagen Bioscience's Accounts Payables averaged around $9.8 million, with its median value being $9.9 million (2021).
  • Per our database at Business Quant, Niagen Bioscience's Accounts Payables plummeted by 2495.11% in 2024 and then surged by 8458.64% in 2025.
  • Over the past 5 years, Niagen Bioscience's Accounts Payables (Quarter) stood at $10.4 million in 2021, then dropped by 7.14% to $9.7 million in 2022, then rose by 5.71% to $10.2 million in 2023, then dropped by 16.67% to $8.5 million in 2024, then surged by 49.45% to $12.7 million in 2025.
  • Its Accounts Payables stands at $12.7 million for Q3 2025, versus $13.7 million for Q2 2025 and $10.6 million for Q1 2025.